TABLE 5.
Demographic variables associated with epigenetic age acceleration in mixed models.
| Potential contributors to epigenetic age acceleration | F-value (p-value)a | |||
|---|---|---|---|---|
| AAR | EEAA | PEAA | aaDNAmTL | |
| Study visit | 17.0 (<0.001) | 42.2 (<0.001) | 22.1 (<0.001) | 55.0 (<0.001) |
| Visit 1 vs. visit 2 | ||||
| HIV group, PLWH vs. SN participants | 125.0 (<0.001) | 147.0 (<0.001) | 134.0 (<0.001) | 192.0 (<0.001) |
| Study visit* | 1.40 (0.24) | 35.1 (<0.001) | 21.5 (<0.001) | 34.1 (<0.001) |
| HIV group | ||||
| Race, non-white vs. white | 0.5 (0.50) | 1.7 (0.20) | 0.3 (0.58) | 29.4 (<0.001) |
| Hepatitis B status, HBsAg– vs. + | 3.3 (0.069) | 0.25 (0.62) | 3.1 (0.077) | 0.07 (0.80) |
| Tobacco smoking, cumulative pack years | 3I73 (0.054) | 1.47 (0.22) | 4.9 (0.027) | 1.6 (0.20) |
| Body mass index, kg/m 2 | 1.1 (0.29) | 0.6 (0.44) | 0.2 (0.68) | 0.3 (0.57) |
AAR, age acceleration residual; EEAA, extrinsic epigenetic age acceleration; PEAA, phenotypic epigenetic age acceleration; aaDNAmTL, age-adjusted DNA methylation-based estimate of telomere length; PLWH, persons living with HIV; SN = HIV seronegative controls; HBsAg, hepatitis B surface antigen.
a: F-values and Pr > F p-values (p-values bold if < 0.05) from mixed models taking all variables into account in all participants at both visits for each epigenetic measure.